News

Eli Lilly's 3-step strategy to dominate the $95 billion obesity market
Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.The company is set to capture 50% ...
CVS dropped Zepbound in standard coverage. What that means for Zepbound users
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?
Wegovy and Zepbound prices fall, but access to the obesity drugs still isn't guaranteed
Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...
UBS Sees Strong Sales Outlook for Eli Lilly’s Zepbound and Mounjaro
According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...
pharmaphorum2d
Lilly launches single-dose Zepbound to ease self-pay access
Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.
pharmaphorum5d
Lilly hit as PBM drops Zepbound, but retains Wegovy
Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...
Forbes4d
Zepbound For Weight Loss: How It Works – Forbes Health
Zepbound should be used in conjunction with a reduced-calorie diet and increased physical activity, according to Eli Lilly and Co., the drug manufacturer.